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Abstract
Background: Identification of prognostic mRNA biomarkers has been done for various cancer types. The data that
are published from such studies are archived in public repositories. There are hundreds of such datasets available
for multiple cancer types in public repositories. Wealth of such data can be utilized to study prognostic implications
of mRNA in different cancers as well as in different populations or subtypes of same cancer.
Description: We have created a web application that can be used for studying prognostic implications of mRNA
biomarkers in a variety of cancers. We have compiled data from public repositories such as GEO, EBI Array Express
and The Cancer Genome Atlas for creating this tool. With 64 patient series from 18 cancer types in our database,
this tool provides the most comprehensive resource available for survival analysis to date. The tool is called
PROGgene and it is available at www.compbio.iupui.edu/proggene.
Conclusions: We present this tool as a hypothesis generation tool for researchers to identify potential prognostic
mRNA biomarkers to follow up with further research. For this reason, we have kept the web application very simple
and straightforward. We believe this tool will be useful in accelerating biomarker discovery in cancer and quickly
providing results that may indicate disease-specific prognostic value of specific biomarkers.
Keywords: Biomarker, Multiple cancer, Survival, Pan cancer, Prognostic, mRNA, Database, Kaplan, Meier, KM
Background
With advent of high throughput transcriptomic profil-
ing, biomarker identification has been taken to the gen-
omic level. Several studies have been published so far
where transcriptomic profiling and consequently bio-
marker identification in form of single genes, or a signa-
ture composed of several genes, has been done on
cancer samples, and such data are available in public do-
main. Gene signatures prognostic for overall, metastasis
free or recurrence free survival have been developed
using transcriptomic profiling. In several such studies
gene signatures have been developed specific for prog-
nostication in particular subtype of a cancer, for in-
stance, a subgroup of population treated with a specific
drug. 70 Gene signature Mammaprint® [1], PAM50 [2],
OncotypeDx® [3] are some examples of gene signatures
of prognostic importance in breast cancer. Similar signa-
tures have also been developed in other cancers such as
Colon cancer [4,5], Liver cancer [6], Lung cancer [7,8]
and Pancreatic Cancer [9] etc. In any case, the primary
endpoint of prognostic assessment is survival analysis,
and patient groups are divided into good and bad prog-
nosis groups based on weighted or un-weighted expres-
sion of individual genes or a group of genes. Although
multiple genes (signatures) provide a stronger and more
reliable prognostic assessment, prognostic effects must
be first studied at individual gene level. Such an analysis
provides rationale for mechanistic studies followed by
therapeutic targeting.
Data pertaining to several cancer studies are available
in public domain. The wealth of data that is available
can be utilized to perform comparative prognostic bio-
marker identification in multiple cancers. Biomarkers
identified using such data as prognostic for one cancer
type can also be studied in other cancer types. As men-
tioned previously, in several studies, biomarkers have
been identified for specific populations; however, tools
to expand these biomarker sets across multiple cancer
types are very limited. Moreover, human genome con-
tains isoforms for several genes that have redundant and
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non-redundant functions. For example, there are three
isoforms for the serine/threonine kinase (AKT) namely
AKT1, AKT2, and AKT3. These isoforms have opposing
role in cancer or being active only in a specific subtype
of cancer. AKT1 promotes tumor growth but inhibits
metastasis, whereas AKT2 promotes metastasis [10,11].
Neuronal cell type enriched AKT3 is over expressed in
estrogen receptor (ER) negative breast cancer and is a
target of frequent translocation in ER-negative but not
ER + breast cancer [12,13]. Since AKT is activated in
50% of cancers, it is critical to determine the ratio be-
tween these isoforms to generate hypothesis regarding
the impact of AKT activation on the course of the
disease. However, tools that can analyze data for such
purposes are not currently available.
In this paper we present a web tool for identifying
prognostic biomarkers in several cancer types. The tool
is called ‘PROGgene’ and is available at www.compbio.
iupui.edu/proggene. Our tool can be used to create
prognostic (Kaplan-Meier, KM) plots for mRNAs of
interest using data in different cancers. To create this
tool we have compiled publicly available data from
repositories such as Gene Expression Omnibus (GEO),
EBI Array Express and recently developed ‘The Cancer
Genome Atlas’ (TCGA). With a total of 64 datasets from
18 cancer types, our tool is the most comprehensive
prognostic biomarker identification tool to date. Cur-
rently tools are available to perform prognostic analysis
on gene expression data coming from public domain, e.
g., KMplot for Breast [14] and Ovarian [15] cancer, and
ITTACA [16] and Prognoscan [17] for multiple cancers.
But these tools suffer from some limitations which are
overcome in our tool as discussed in the sections ahead.
Using PROGgene, users can also divide data into several
subgroups based on covariates available for dataset of
interest. For e.g., prognostic plots can be created by div-
iding the patient series into groups of patients treated
and not treated with chemotherapy, or groups at differ-
ent stages of disease. The web application provides a list
of datasets available for analysis of interest and lets re-
searcher choose the most pertinent datasets for their
study design. Researchers may look for more informa-
tion on datasets providing promising plots in the source
repositories with links provided on the results page to
further identifying the study characteristics they are
looking for.
We believe that this tool would prove to be an import-
ant hypothesis generation tool for researchers working
in area of cancer. Since more and more datasets are
being continually uploaded in the public repositories, we
would survey the public repositories periodically for
newly uploaded data to extend the repository of datasets.
We are not planning to implement any automated data
retrieval tool from these repositories to deposit new data
in our database. Rather we would manually curate and
process the data before it is available in our dataset for
the reason that every dataset requires different parame-
ters for processing. In planned future version of our tool,
we would also like to produce more informative graphs
by introducing adjustments for survival covariates in
survival analysis. Researchers who cannot see datasets of
their interest in our repository can also request addition
of datasets using contact information provided on the
website.
Construction and content
Data
We have compiled data on 64 patient series’ in our data-
base. Additional file 1: Table S1 lists the datasets avail-
able in our database with information on data source,
platform of transcriptomic profiling, number of samples
(after screening off samples that did not have relevant
survival related information) in the series and number of
genes available. A distribution of samples and genes in
the database is also provided in Figure 1. In majority of
the series, we have downloaded raw data from the public
repositories and processed the data ourselves. Data pre-
processing was done in following ways
a) For datasets where preprocessed data were
downloaded from public repositories (such as series
matrices from GEO), no further processing of data
was done.
b) For datasets where raw data profiled on Affymetrix
arrays was downloaded, data were imported into
Partek Genomics Suite (v 6.5) (PGS) using RMA
background correction. If batch effect was present in
the data due to samples being profiled in separate
batches, it was removed using PGS’s batch effect
removal tool. Finally, probe level data was collapsed
to gene level data by retaining only the probe with
maximum coefficient of variation across all samples,
and discarding the rest of probes for genes that were
profiled on multiple probes.
c) For datasets where raw data profiled on Illumina
platform were downloaded, probes that showed
insufficient signal and p values across more than
20% of samples were discarded. For the probes that
remained, they were collapsed to gene level data in a
way similar to that for Affymetrix data.
For all the data, final probability distributions for all
samples were checked manually using PGS (data not
shown). Datasets that showed an abnormal distribution
of genomic profiles were discarded. Additional file 2:
Table S2 lists various survival variables associated with
available datasets. For all other cancers except breast
cancer, we have one or more of Overall, Metastasis free
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Figure 1 Descriptive statistics on datasets included in PROGgene database. (A) No of samples per dataset available in PROGgene. (B) No of
genes profiled in each dataset available in PROGgene.
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and Recurrence free survival variables. For Breast cancer,
apart from overall, metastasis free and recurrance free
survival, for some datasets Lung and Brain Metastasis
free survival measures are also available. Additional file
3: Table S3 enlists covariates available for the different
datasets. Additional file 4: Table S4 enlists for each data-
sets, number of samples, median and minimum and
maximum survival times associated with various survival
functions available for the dataset.
Web application
Our tool is a web application created using PHP5 [18]
and R Programming environment (v2.15.2), with MySQL
(v 5.0.95) [19] database in the backend. Survival calcula-
tions are done in our tool using R library ‘Survival’
which is also coded in the backend. The web application
consists of Home page where users can input gene(s) of
interest and select cancer type in which they want to
create prognostic plots. Here users can also select the
survival function they want to study such as overall sur-
vival or metastasis free survival or recurrence free sur-
vival. Upon submitting the information in home page, a
list of all datasets which are relevant to the current ana-
lysis parameters is displayed. Users can select datasets
they want to visualize prognostic plots in from the list
on filter page. Upon submitting information on this
page, prognostic plots are calculated by backend scripts
and results are displayed on the results page. If more
than one datasets are available for selected cancer type
for selected parameters, prognostic plots are displayed
separately for each dataset. If covariates are selected for
dividing the data, for each dataset, besides the global
plot, prognostic plots are also shown for data divided by
covariates. When multiple genes are being studied, the
application also produces a plot for average gene expres-
sion for full signature. In case of gene signature, data
division by covariates is not done, and only global signa-
ture plots are provided. The tool also indicates whether
expression data for one or more genes in the signature is
not available in any dataset.
Workflow
To create prognostic plots our tool uses R library
'Survival'. A line diagram depicting workflow of our tool
is provided in Figure 2. Although prognostic plots can be
created for multiple genes using their average expression
in our tool, for the purpose of illustrating methodology,
we would explain how prognostic plots are created for a
single gene. Users enter gene symbol and select cancer
type in the home page of our tool. For selected cancer
type, all datasets available are retrieved. In each dataset,
for the selected gene, survival information in terms of
survival status (overall or metastasis free or recurrence
free survival), and survival time (time to death or time
to metastasis or time to recurrence) are retrieved along
with gene expression as continuous variable. Using me-
dian gene expression value as bifurcating point, samples
are divided into High and Low gene expression groups.
Using survival data and continuous expression variable,
survival analysis is done by fitting cox proportional
Figure 2 Flowchart depicting workflow of PROGgene program.
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hazards model using function “coxph” of library survival.
Hazard ratio (HR) as ‘exp(coef)’ and log rank p value are
retrieved from the fitted model. To create prognostic
plot, High and Low expression categorical variable is
used along with survival data. Plots are created using
function ‘survfit’ of the same R library. Final plots, which
show survival in High and Low expression arms of sam-
ples, annotated for HR, HR confidence intervals and
p value are exported as ‘.png’ images, which are
displayed on the results page.
Utility and discussion
We assessed the performance of our tool by creating
prognostic plots for recently published biomarker signa-
tures as case studies using our tool. In majority of cases
the prognostic plots created by our tool corroborated
with the published findings (data not shown). In first
case study, we created prognostic plots for genes associ-
ated with poor and good outcomes in the 70 gene Mam-
maprint® signature for breast cancer. The 70-gene
signature was identified in node negative breast cancer
samples and predicts outcome as time to metastasis in
such patients. Of the 70 genes in the signature roughly
70% genes are over expressed in poor prognosis group
while the rest are under expressed in the same group
compared to the good prognosis group. In this study we
created prognostic plots using our application for good
and bad prognosis related genes in Mammaprint signa-
ture in two external datasets–NKI dataset [20] and
GSE11121 [21]. GSE11121 was chosen as the second
dataset as it also consists of node negative tumor sam-
ples. Figure 3 shows combined prognostic plots for
genes up and down regulated in 70-gene signature sep-
arately in the two datasets. Although all the genes in
Figure 3 Prognostic Plots created with PROGgene for published signatures in Breast Cancer. (A) Combined prognostic plot for genes
down regulated in poor prognosis group in 70 gene Mammaprint signature of breast cancer in GSE11121, (B) Combined prognostic plot for
genes up regulated in poor prognosis group in 70 gene Mammaprint signature of breast cancer in GSE11121, (C) Combined prognostic plot for
genes down regulated in poor prognosis group in 70 gene Mammaprint signature of breast cancer in NKI dataset, (D) Combined prognostic plot
for genes up regulated in poor prognosis group in 70 gene Mammaprint signature of breast cancer in NKI dataset.
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Figure 4 Prognostic Plots created with PROGgene for published signatures in TCGA Ovarian Cancer. (A) Combined prognostic plot for
genes up regulated in poor prognosis group in 193 gene TCGA signature for Ovarian cancer in GSE32062, (B) Combined prognostic plot for
genes down regulated in poor prognosis group in 193 gene TCGA signature for Ovarian cancer in GSE32062.
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Mammaprint signature were not found in these datasets,
the resulting plots for sum of found genes corroborates
in external datasets with the findings in the published
work. In another case study, we tried to validate the
gene signature developed by the Cancer Genome Atlas
consortium for predicting overall survival in ovarian
cystadenocarcinoma. The TCGA consortium identified a
193 gene signature predictive of overall survival in high
stage and grade ovarian cystadenocarcinoma patients.
The signature consists of 108 genes associated with poor
prognosis and 85 genes associated with good prognosis.
We created plots for both subsets of genes in external
dataset GSE32062 [22] which comprises of samples from
high grade and stage ovarian cancer patients. Some
genes from the TCGA signature were not present in this
dataset, but the plots for combination of rest of the
genes from the two subsets again corroborated with the
directions identified in the TCGA publication (Figure 4).
Our tool is primarily a hypothesis generation tool,
which is meant to provide pursuable gene biomarkers in
cancers of choice. Our database contains data from 64
unique patient series’, amounting to a total of approxi-
mately 11,800 samples profiled over a maximum of ap-
proximately 24,000 markers in 18 cancer types. Patient
samples in the datasets come from a variety of popula-
tions and expression profiling platforms. The web appli-
cation implements traditional survival analysis toolkit
using data from public repositories and is thus a pipeline
rather than a novel method.
Our tool has significant advantages over other con-
temporary similar tools. First, with 18 cancer types our
tool is the most comprehensive tool to date for survival
analysis and can be used by researchers working on a
wide array of cancer types. Secondly, our tool does not
merge data coming from different studies (having differ-
ent characteristics) and platforms, which may in certain
situations, become erroneous. Third, an indirect advan-
tage of this strategy is that researchers can identify study
characteristics where their potential biomarkers may not
work at all or may have an inverse effect. Tools like
ITTACA are not primarily survival analysis tools and
thus, do not have capability of producing survival plots
for a lot of different cancer types and studies. ITTACA
comprises data for only 7 cancer types and is capable of
conducting survival analysis on only a few cancer types
using data from only a limited number of studies. Prog-
noScan although compiles data for 14 cancer types, does
not include recent major datasets such as TCGA data,
and also cannot be used to study prognostic implications
of multiple genes (signatures). KMplot for Breast and
Ovarian Cancer suffer from inherent over fitting of data
as they normalize gene expression data coming from
several different studies and to pool one large patient
series, in an attempt to provide meta-analysis. Merging
of dataset using currently available algorithms can be
performed on datasets profiled only on same platform
for optimal results. For this reason, KMplot merges data
coming from a single gene expression profiling platform.
Although a very robust tool, this strategy in KMplot may
lead to misleading results when studying biomarkers
identified on other platforms. For instance, Crijns et. al.
[23] identified an 86 gene signature predictive of overall
survival in high risk (high grade and stage) ovarian can-
cer patients. Gene expression in this study was profiled
on custom microarray platform. We tried to plot prog-
nostic plot for this signature using KMPlot and PROG-
gene separately. For 60 genes from the signature whose
decreased expression is associated with higher risk (low
overall survival rate), Affymetrix probe IDs (usable in
KMplot) were available for only 30 genes. Using these
probe Ids KMplot failed to produce statistically signifi-
cant KM plot for this group of genes (P > 0.1) using high
stage (3 + 4) and grade (3) as study parameters. For the
same signature we also performed survival analysis using
KMplot for the group of genes whose higher expression
is associated with high risk. This analysis also failed to
produce statistically significant results. For the same
group of genes, using PROGgene we were able to pro-
duce a significant prognostic plot using datasets which
comprise of gene expression profiling of high stage and
grade ovarian cancer patients (GSE32062 and TCGA,
see Additional file 5).
In PROGgene we have kept gene expression data com-
ing from same patient series, but profiled on different
platforms separate. The motivation behind providing
study specific prognostic plots rather than a pooled
prognostic plot is because we believe researchers are
more interested in analyzing data which is more pertin-
ent to their specific design for hypothesis generation.
Datasets which do not contain any information relevant
to such specific study designs may lead to irrelevant
information. Although, this limits sample size in some
series, we believe this approach is highly suitable for hy-
pothesis generation as it provides prognostic plots per-
taining to different subpopulations of cancers separately,
and does not perform any over-fitting of the data. An-
other reason for not merging data from different studies
is that many of studies have been conducted using
microarray platforms and these platforms are becoming
obsolete. The focus of Transcriptomic profiling technol-
ogy is shifting more and more towards sequencing. With
evolving sequencing technology it is not possible to
merge gene expression profiles profiled in different
experiments together.
In future versions of the tool, we would like to add
more variables to our database as more and more inte-
grated data repositories such as TCGA evolve. We also
plan to incorporate adjusting of survival models for
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covariates such as age, therapy, sex, hormonal statuses
etc., for providing more informative prognostic plots to
the researchers. As more and more data becomes avail-
able, such incorporations are possible.
Conclusion
Prognostic biomarker identification, which may include
genes, polymorphisms, mutations, micromolecules, or
epigenetic regulators, is one of the major contributions
of cancer genomics. Cancer research predominantly
focuses on specific patient populations for biomarker
identification. We believe that this application will prove
useful to researchers working on cancers to identify po-
tential gene biomarker targets for hypothesis generation
and designing mechanistic studies. Our tool uses data
pertaining to specific patient population as published in
studies. It allows users to divide data in specific studies
by available covariates and analyze different survival
functions on such divided data. This allows researchers
to study biomarkers in specific patient populations with-
out the problem of over fitting the data. Future version
of our tools will also allow researchers to adjust survival
models for different covariates and will provide more
intuitive plots.
Availability and requirements
The tool is a web application and is available freely for
academic and research purposes at following URL www.
compbio.iupui.edu/proggene.
Additional files
Additional file 1: Table S1. Table enlisting various datasets available in
PROGgene.
Additional file 2: Table S2. Table enlisting various survival measures
available for the datasets available in PROGgene.
Additional file 3: Table S3. Table enlisting the covariates associated
with the datasets available in PROGgene. These covariates can be used to
divide data for creating prognostic plots for subpopulations within one
dataset.
Additional file 4: Table S4. Table enlisting descriptive statistics such as
sample size, max, median and min survival times associated with datasets
available in PROGgene.
Additional file 5: Prognostic plots created using KMPlot and
PROGgene for gene signature identified as predictive of high risk
(overall survival) in ovarian cancer by Crijns et. al.
Abbreviations
TCGA: The cancer genome atlas; HR: Hazard ratio; KM: Kaplan meier;
PGS: Partek genomics suite.
Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
CG carried out study planning, data procurement, quality assurance, data
analysis, programming and web development, and manuscript preparation
for the article. HN contributed to study planning and manuscript
preparation. Both authors read and approved the final manuscript.
Funding
This study was partly supported by IUPUI Breast Cancer Signature Center and
Susan G. Komen for the Cure grant SAC110025 (to HN).
Financial disclosure
The authors hereby declare no financial disclosures.
Author details
1Thomas Jefferson University Hospitals, 117 S 11th Street, Suite 207,
Philadelphia, PA 19107, USA. 2Departments of Surgery, Biochemistry and
Molecular Biology, Indiana University School of Medicine, Indianapolis, IN
46202, USA.
Received: 26 August 2013 Accepted: 20 October 2013
Published: 28 October 2013
References
1. Buyse M, Loi S, van’t Veer L, et al: TRANSBIG consortium: validation and
clinical utility of a 70-gene prognostic signature for women with
node-negative breast cancer. J Natl Cancer Inst 2006, 98(17):1183–1192.
2. Parker JS, Mullins M, Cheang MC, et al: Supervised risk predictor of breast
cancer based on intrinsic subtypes. J Clin Oncol 2009, 27(8):1160–1167.
3. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of
tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004,
351(27):2817–2826.
4. Tan IB, Tan P: Genetics: an 18-gene signature (ColoPrint®) for colon
cancer prognosis. Nat Rev Clin Oncol 2011, 8(3):131–133.
5. Yi JM, Dhir M, Van Neste L, et al: Genomic and epigenomic integration
identifies a prognostic signature in colon cancer. Clin Cancer Res 2011,
17(6):1535–1545.
6. Budhu A, Forgues M, Ye QH, et al: Prediction of venous metastases,
recurrence, and prognosis in hepatocellular carcinoma based on a
unique immune response signature of the liver microenvironment.
Cancer Cell 2006, 10(2):99–111.
7. Lu Y, Lemon W, Liu PY, et al: A gene expression signature predicts
survival of patients with stage I non-small cell lung cancer. PLoS Med
2006, 3(12):e12.
8. Hsu YC, Yuan S, Chen HY, et al: A four-gene signature from NCI-60 cell
line for survival prediction in non-small cell lung cancer. Clin Cancer Res
2009, 15(23):7309–7315.
9. Sergeant G, Van Eijsden R, Roskams T, Van Duppen V, Topal B: Pancreatic
cancer circulating tumour cells express a cell motility gene signature
that predicts survival after surgery. BMC Cancer 2012, 12(1):527.
10. Iliopoulos D, Polytarchou C, Hatziapostolou M, et al: MicroRNAs
differentially regulated by Akt isoforms control EMT and stem cell
renewal in cancer cells. Sci Signal 2009, 2(92):ra62.
11. Heron-Milhavet L, Khouya N, Fernandez A, Lamb NJ: Akt1 and Akt2:
differentiating the aktion. Histol Histopathol 2011, 26(5):651–662.
12. Nakatani K, Thompson DA, Barthel A, et al: Up-regulation of Akt3 in
estrogen receptor-deficient breast cancers and androgen-independent
prostate cancer lines. J Biol Chem 1999, 274(31):21528–21532.
13. Banerji S, Cibulskis K, Rangel-Escareno C, et al: Sequence analysis of
mutations and translocations across breast cancer subtypes. Nature 2012,
486(7403):405–409.
14. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z:
An online survival analysis tool to rapidly assess the effect of 22,277
genes on breast cancer prognosis using microarray data of 1809
patients. Breast Cancer Res Treat 2010, 123(3):725–731.
15. Gyorffy B, Lanczky A, Szallasi Z: Implementing an online tool for genome-wide
validation of survival-associated biomarkers in ovarian-cancer using
microarray data of 1287 patients. Endocr Relat Cancer 2012, 19(2):197–208.
16. Elfilali A, Lair S, Verbeke C, La Rosa P, Radvanyi F, Barillot E: ITTACA: a new
database for integrated tumor transcriptome array and clinical data
analysis. Nucleic Acids Res 2006, 34(Database issue):D613–D616.
17. Mizuno H, Kitada K, Nakai K, Sarai A: PrognoScan: a new database for
meta-analysis of the prognostic value of genes. BMC Med Genomics 2009,
2:18.
18. www.php.net.
19. www.mysql.com.
Goswami and Nakshatri Journal of Clinical Bioinformatics 2013, 3:22 Page 8 of 9
http://www.jclinbioinformatics.com/content/3/1/22
20. van de Vijver MJ, He YD, van’t Veer LJ, et al: A gene-expression signature
as a predictor of survival in breast cancer. N Engl J Med 2002,
347(25):1999–2009.
21. Schmidt M, Böhm D, Von Törne C, et al: The humoral immune system has
a key prognostic impact in node-negative breast cancer. Cancer Res 2008,
68(13):5405–5413. Doi: 10.1158/0008-5472.CAN-07-5206.
22. Yoshihara K, Tsunoda T, Shigemizu D, et al: High-risk ovarian cancer based
on 126-gene expression signature is uniquely characterized by
downregulation of antigen presentation pathway. Clin Cancer Res 2012,
18(5):1374–1385.
23. Crijns AP, Fehrmann RS, De Jong S, Gerbens F, Meersma GJ, Klip HG,
Hollema H, Hofstra RM, Te Meerman GJ, De Vries EG, van der Zee AG:
Survival-related profile, pathways, and transcription factors in ovarian
cancer. PLoS Med 2009, 6(2):e24.
doi:10.1186/2043-9113-3-22
Cite this article as: Goswami and Nakshatri: PROGgene: gene expression
based survival analysis web application for multiple cancers. Journal of
Clinical Bioinformatics 2013 3:22.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Goswami and Nakshatri Journal of Clinical Bioinformatics 2013, 3:22 Page 9 of 9
http://www.jclinbioinformatics.com/content/3/1/22
